Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
BACKGROUND: Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiatio...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797097931306696704 |
|---|---|
| author | James, R Glynne-Jones, R Meadows, H Cunningham, D Myint, A Saunders, M Maughan, T McDonald, A Essapen, S Leslie, M Falk, S Wilson, C Gollins, S Begum, R Ledermann, J Kadalayil, L Sebag-Montefiore, D |
| author_facet | James, R Glynne-Jones, R Meadows, H Cunningham, D Myint, A Saunders, M Maughan, T McDonald, A Essapen, S Leslie, M Falk, S Wilson, C Gollins, S Begum, R Ledermann, J Kadalayil, L Sebag-Montefiore, D |
| author_sort | James, R |
| collection | OXFORD |
| description | BACKGROUND: Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival. METHODS: In this 2 × 2 factorial trial, we enrolled patients with histologically confirmed squamous-cell carcinoma of the anus without metastatic disease from 59 centres in the UK. Patients were randomly assigned to one of four groups, to receive either mitomycin (12 mg/m(2) on day 1) or cisplatin (60 mg/m(2) on days 1 and 29), with fluorouracil (1000 mg/m(2) per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions); with or without two courses of maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14). The random allocation was generated by computer and patients assigned by telephone. Randomisation was done by minimisation and stratified by tumour site, T and N stage, sex, age, and renal function. Neither patients nor investigators were masked to assignment. Primary endpoints were complete response at 26 weeks and acute toxic effects (for chemoradiation), and progression-free survival (for maintenance). The primary analyses were done by intention to treat. This study is registered at controlled-trials.com, number 26715889. FINDINGS: We enrolled 940 patients: 472 were assigned to mitomycin, of whom 246 were assigned to no maintenance, 226 to maintenance; 468 were assigned to cisplatin, of whom 246 were assigned to no maintenance, 222 to maintenance. Median follow-up was 5.1 years (IQR 3.9-6.9). 391 of 432 (90.5%) patients in the mitomycin group versus 386 of 431 (89.6%) in the cisplatin group had a complete response at 26 weeks (difference -0.9%, 95% CI -4.9 to 3.1; p=0.64). Overall, toxic effects were similar in each group (334/472 [71%] for mitomycin vs 337/468 [72%] for cisplatin). The most common grade 3-4 toxic effects were skin (228/472 [48%] vs 222/468 [47%]), pain (122/472 [26%] vs 135/468 [29%]), haematological (124/472 [26%] vs 73/468 [16%]), and gastrointestinal (75/472 [16%] vs 85/468 [18%]). 3-year progression-free survival was 74% (95% CI 69-77; maintenance) versus 73% (95% CI 68-77; no maintenance; hazard ratio 0.95, 95% CI 0.75-1.21; p=0.70). INTERPRETATION: The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK. FUNDING: Cancer Research UK. |
| first_indexed | 2024-03-07T05:02:22Z |
| format | Journal article |
| id | oxford-uuid:d8ba9708-0cb7-4a8d-8038-d49b2e3a1076 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:02:22Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:d8ba9708-0cb7-4a8d-8038-d49b2e3a10762022-03-27T08:50:59ZMitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d8ba9708-0cb7-4a8d-8038-d49b2e3a1076EnglishSymplectic Elements at Oxford2013James, RGlynne-Jones, RMeadows, HCunningham, DMyint, ASaunders, MMaughan, TMcDonald, AEssapen, SLeslie, MFalk, SWilson, CGollins, SBegum, RLedermann, JKadalayil, LSebag-Montefiore, DBACKGROUND: Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival. METHODS: In this 2 × 2 factorial trial, we enrolled patients with histologically confirmed squamous-cell carcinoma of the anus without metastatic disease from 59 centres in the UK. Patients were randomly assigned to one of four groups, to receive either mitomycin (12 mg/m(2) on day 1) or cisplatin (60 mg/m(2) on days 1 and 29), with fluorouracil (1000 mg/m(2) per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions); with or without two courses of maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14). The random allocation was generated by computer and patients assigned by telephone. Randomisation was done by minimisation and stratified by tumour site, T and N stage, sex, age, and renal function. Neither patients nor investigators were masked to assignment. Primary endpoints were complete response at 26 weeks and acute toxic effects (for chemoradiation), and progression-free survival (for maintenance). The primary analyses were done by intention to treat. This study is registered at controlled-trials.com, number 26715889. FINDINGS: We enrolled 940 patients: 472 were assigned to mitomycin, of whom 246 were assigned to no maintenance, 226 to maintenance; 468 were assigned to cisplatin, of whom 246 were assigned to no maintenance, 222 to maintenance. Median follow-up was 5.1 years (IQR 3.9-6.9). 391 of 432 (90.5%) patients in the mitomycin group versus 386 of 431 (89.6%) in the cisplatin group had a complete response at 26 weeks (difference -0.9%, 95% CI -4.9 to 3.1; p=0.64). Overall, toxic effects were similar in each group (334/472 [71%] for mitomycin vs 337/468 [72%] for cisplatin). The most common grade 3-4 toxic effects were skin (228/472 [48%] vs 222/468 [47%]), pain (122/472 [26%] vs 135/468 [29%]), haematological (124/472 [26%] vs 73/468 [16%]), and gastrointestinal (75/472 [16%] vs 85/468 [18%]). 3-year progression-free survival was 74% (95% CI 69-77; maintenance) versus 73% (95% CI 68-77; no maintenance; hazard ratio 0.95, 95% CI 0.75-1.21; p=0.70). INTERPRETATION: The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK. FUNDING: Cancer Research UK. |
| spellingShingle | James, R Glynne-Jones, R Meadows, H Cunningham, D Myint, A Saunders, M Maughan, T McDonald, A Essapen, S Leslie, M Falk, S Wilson, C Gollins, S Begum, R Ledermann, J Kadalayil, L Sebag-Montefiore, D Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. |
| title | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. |
| title_full | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. |
| title_fullStr | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. |
| title_full_unstemmed | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. |
| title_short | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. |
| title_sort | mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous cell carcinoma of the anus act ii a randomised phase 3 open label 2 2 factorial trial |
| work_keys_str_mv | AT jamesr mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT glynnejonesr mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT meadowsh mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT cunninghamd mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT myinta mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT saundersm mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT maughant mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT mcdonalda mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT essapens mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT lesliem mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT falks mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT wilsonc mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT gollinss mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT begumr mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT ledermannj mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT kadalayill mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial AT sebagmontefiored mitomycinorcisplatinchemoradiationwithorwithoutmaintenancechemotherapyfortreatmentofsquamouscellcarcinomaoftheanusactiiarandomisedphase3openlabel22factorialtrial |